Alterity Therapeutics Releases April 2026 Corporate Presentation

Alterity Therapeutics Limited filed a Form 6-K with the SEC on April 1, 2026, to provide a Corporate Presentation for April 2026. As a development-stage enterprise, the company uses these presentations to update investors on its strategic direction and clinical pipeline. While the filing incorporates the presentation by reference into several existing Registration Statements (Forms S-8 and F-3), it does not disclose new clinical trial results, regulatory approvals, or specific financial data within the primary document. The filing serves as a routine regulatory update to ensure current corporate information is available to the public and linked to its active securities registrations. No specific upcoming trial result dates were mentioned in the summary text of the 6-K filing.